Le programme L.E.A., suivi prolongé après traitement d'une leucémie aiguë de l'enfance : structuration, résultats et perspectives

Patients surviving childhood cancer are exposed to a wide range of late side effects. In this context, structuring large prospective cohorts is crucial to improve patients' medical care as well as our knowledge on the subject. The L.E.A. program (for Leucémie Enfants Adolescents), dedicated to patients cured after childhood leukemia treatment, is based on the creation of a multi-centric prospective cohort in 13 French pediatric cancer centers. Data are collected during specific medical visits and include information on the initial disease and its treatments, physical side effects, quality of life, socioprofessional insertion and relationships with the health-care system. At the end of the year 2012, 2162 patients have been included in the program, half of them being evaluated at least twice. The total number of L.E.A. evaluations was 3519 and the mean follow-up duration from diagnosis to last evaluation was 12 years. The scientific output of the L.E.A. cohort includes several papers published since 2007. A selection of 4 studies from L.E.A. is presented in the following text. The reported subjects are: the metabolic syndrome; bone mineral density abnormalities; osteonecrosis; cataract.